A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis -specific T-cell responses in human

Highlights • Novel liposome based adjuvant formulation CAF01 safe in first-in-human clinical trial. • H1 antigen + CAF01 adjuvant induce T-cell responses in human. • T-cell immunity is very long-lasting, specific responses detectable up to 150 weeks.

Saved in:
Bibliographic Details
Published in:Vaccine 2014-12, Vol.32 (52), p.7098-7107
Main Authors: van Dissel, Jaap T, Joosten, Simone A, Hoff, Søren T, Soonawala, Darius, Prins, Corine, Hokey, David A, O’Dee, Dawn M, Graves, Andrew, Thierry-Carstensen, Birgit, Andreasen, Lars V, Ruhwald, Morten, de Visser, Adriëtte W, Agger, Else Marie, Ottenhoff, Tom H.M, Kromann, Ingrid, Andersen, Peter
Format: Article
Language:English
Subjects:
Adjuvant
Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - adverse effects
Adolescent
Adult
Allergy and Immunology
Applied microbiology
Bacteriology
Biological and medical sciences
Clinical trial
Female
Fundamental and applied biological sciences. Psychology
Healthy Volunteers
Humans
Immunogenicity
Immunologic Memory
Liposomes - administration & dosage
Male
Microbiology
Middle Aged
Miscellaneous
Mycobacterium
Mycobacterium tuberculosis - immunology
Recombinant Fusion Proteins - administration & dosage
Recombinant Fusion Proteins - immunology
Recombinant Fusion Proteins - toxicity
T-Lymphocytes - immunology
Tuberculosis
Tuberculosis Vaccines - administration & dosage
Tuberculosis Vaccines - adverse effects
Tuberculosis Vaccines - immunology
Vaccine
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Novel liposome based adjuvant formulation CAF01 safe in first-in-human clinical trial. • H1 antigen + CAF01 adjuvant induce T-cell responses in human. • T-cell immunity is very long-lasting, specific responses detectable up to 150 weeks.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.10.036